GM102

DRUG2 trials

Sponsors

GamaMabs Pharma

Conditions

Colorectal CancerNeoplasm, Gynecologic

Phase 1

First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers

CompletedNCT02978755

GamaMabs PharmaNeoplasm, Gynecologic

Start: 2016-06-30End: 2020-06-10Updated: 2022-04-06

Phase 2

Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers

CompletedNCT03799731

GamaMabs PharmaColorectal Cancer

Start: 2018-07-11End: 2021-02-10Updated: 2022-04-14

Related Papers

Circulating CD14<sup>high</sup> CD16<sup>low</sup> intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression

Journal for ImmunoTherapy of Cancer2020-06-0144 citations

First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts).

Journal of Clinical Oncology2019-05-202 citations

A first-in-human study of monoclonal antibody GM102 in patients with anti-Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.

Journal of Clinical Oncology2018-05-204 citations